NCT05438836 Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
| NCT ID | NCT05438836 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Herlev Hospital |
| Condition | Anal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 205 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 205 participants in total. It began in 2022-01-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Eligibility Criteria
Inclusion Criteria: * Biopsy-verified anal cancer * Eligible for curative intended radiotherapy * Written and oral consent Exclusion Criteria: * Other malignant disease within the past 5 years (excluding basal cell carcinoma)
Contact & Investigator
Eva S Serup-Hansen, MD, PhD
PRINCIPAL INVESTIGATOR
Herlev og Gentofte Hospital
Frequently Asked Questions
Who can join the NCT05438836 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05438836 currently recruiting?
Yes, NCT05438836 is actively recruiting participants. Contact the research team at eva.serup-hansen@regionh.dk for enrollment information.
Where is the NCT05438836 trial being conducted?
This trial is being conducted at Herlev, Denmark.
Who is sponsoring the NCT05438836 clinical trial?
NCT05438836 is sponsored by Herlev Hospital. The principal investigator is Eva S Serup-Hansen, MD, PhD at Herlev og Gentofte Hospital. The trial plans to enroll 205 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.